Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURABOLIN vs ERGOSTAT
Head-to-head clinical comparison of therapeutic indices and safety profiles.
DURABOLIN (nandrolone phenpropionate) is an anabolic steroid that binds to androgen receptors, increasing protein synthesis and nitrogen retention, promoting muscle growth and bone density. It also stimulates erythropoietin production, increasing red blood cell mass.
Ergostat (ergotamine) is a serotonin (5-HT) receptor agonist, specifically at 5-HT1B and 5-HT1D receptors, leading to cranial vasoconstriction and inhibition of neurogenic inflammation. It also has partial agonist/antagonist activity at alpha-adrenergic receptors.
Adjunctive therapy to promote weight gain after severe illness, surgery, or trauma,Osteoporosis (off-label),Anemia of renal failure (off-label),HIV/AIDS wasting syndrome (off-label)
FDA-approved: Acute treatment of migraine headache with or without aura,Off-label: Cluster headache, vascular headache
100-200 mg intramuscularly every 1-2 weeks for testosterone replacement; for wasting syndromes, 50-100 mg intramuscularly weekly.
0.2 mg intramuscularly or intravenously every 2-4 hours for maximum 5 doses; not to exceed 1 mg total dose.
Terminal elimination half-life: 4-6 days (intramuscular depot), reflecting slow release from injection site and enterohepatic recirculation; clinical steady-state achieved after 3-6 weeks.
Terminal half-life is 2–3 hours (intravenous) and 2–4 hours (oral). Short half-life necessitates frequent dosing; duration of action limited to 2–4 hours.
Hepatic metabolism via reduction and conjugation; primarily excreted in urine as metabolites (e.g., 19-norandrosterone and 19-noretiocholanolone).
No specific guidelines; use caution in severe impairment (Cr Cl <30 m L/min) due to fluid retention and potential edema.
No specific adjustment; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to risk of cholestasis and hepatotoxicity.
Anabolic steroids may cause peliosis hepatis, liver cell tumors, and blood lipid changes associated with increased cardiovascular risk. Prolonged use can lead to azoospermia, oligospermia, and impotence. Not approved for enhancing athletic performance.
DURABOLIN (nandrolone) is contraindicated in pregnancy. Androgens can cause virilization of the female fetus. First trimester exposure risks clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimester exposure may lead to clitoromegaly and advanced bone age. Fetal growth restriction and preterm birth are also reported.
Ergostat (ergonovine) is contraindicated in pregnancy due to its potent uterotonic effects, which can cause uterine tetany, fetal hypoxia, and placental abruption. It is classified as FDA Pregnancy Category X. Use in the first trimester may increase the risk of spontaneous abortion; in the second and third trimesters, it can precipitate preterm labor and fetal distress. There is no evidence of structural teratogenicity from direct drug effects, but the potential for ischemic injury to the fetus due to uterine hyperstimulation exists.
Durabolin (nandrolone phenylpropionate) is an injectable anabolic steroid with a shorter ester than nandrolone decanoate, allowing for faster onset and offset. Monitor liver function tests and lipid profiles, as it can cause HDL suppression and LDL elevation. Use with caution in patients with pre-existing cardiac, hepatic, or renal disease. Suppresses endogenous testosterone; consider testosterone replacement during and after therapy. Detectable on doping tests for up to 18 months in athletes; educate accordingly.
ERGOSTAT (ergonovine) is an ergot alkaloid used for postpartum hemorrhage. It causes sustained uterine contraction. Contraindicated in hypertension, preeclampsia, and vascular disease. Administer IM or IV slowly over 1 minute to avoid severe vasoconstriction. Monitor blood pressure and uterine tone closely. Do not use in patients with hypersensitivity to ergot alkaloids.
No interactions on record
No interactions on record
DURABOLIN and ERGOSTAT are distinct pharmacological agents. DURABOLIN belongs to the Anabolic Androgenic Steroid class and is primarily used for Adjunctive therapy to promote weight gain after severe illness, surgery, or traumaOsteoporosis (off-label)Anemia of renal failure (off-label)HIV/AIDS wasting syndrome (off-label). ERGOSTAT belongs to the Ergot Alkaloid Antimigraine class and is primarily used for FDA-approved: Acute treatment of migraine headache with or without auraOff-label: Cluster headache, vascular headache. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DURABOLIN carries a safety status of Category C, whereas ERGOSTAT safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via CYP3A4. Undergoes extensive first-pass metabolism.
Primarily renal: 90% as metabolites (glucuronide and sulfate conjugates), 10% unchanged; negligible biliary/fecal elimination.
Primarily hepatic (biliary-fecal) elimination: ~90% of a dose is excreted in feces as metabolites; renal excretion accounts for <5% unchanged drug.
85-95% bound to sex hormone-binding globulin (SHBG) and albumin; high affinity for SHBG, reducing free active fraction.
~65% bound to plasma albumin. Metabolites are less extensively bound.
4-6 L/kg, indicating extensive tissue distribution, particularly to skeletal muscle, bone, and prostate.
Approximately 0.2–0.3 L/kg, indicating primarily extracellular and peripheral tissue distribution with limited CNS penetration.
Intramuscular: ~100% (depot formulation); oral: negligible (<1% due to first-pass hepatic metabolism).
Oral: ~10–20% (extensive first-pass metabolism); Sublingual: ~50–60% (avoids portal circulation); Rectal: ~30–40% (variable).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Not recommended in children due to premature epiphyseal closure and potential virilization; limited data, use only under expert supervision for delayed growth.
Intravenous: 0.1 mg/m² body surface area every 2-4 hours, maximum 0.5 mg total; intramuscular: 0.2 mg every 2-4 hours, maximum 1 mg.
Initiate at lowest effective dose (e.g., 50 mg IM every 2 weeks) due to increased risk of prostatic hypertrophy, fluid retention, and polycythemia.
Start at 0.1 mg intramuscularly or intravenously; monitor for hypertension with higher doses.
Concomitant use with strong CYP3A4 inhibitors (e.g., protease inhibitors, macrolide antibiotics, azole antifungals) can lead to serious and/or life-threatening peripheral ischemia and vasospasm. Avoid coadministration.
Risk of hepatic dysfunction, peliosis hepatis, hepatocellular carcinoma, hyperlipidemia, cardiovascular disease, edema, hypertension, glucose intolerance, premature closure of epiphyseal growth plates in children, virilization in women, and prostate hypertrophy in men. Monitor liver function, lipid profile, and hematocrit. Use with caution in patients with cardiac, renal, or hepatic disease.
Known hypersensitivity to nandrolone or any component, pregnant or breastfeeding women, men with carcinoma of the breast or prostate, nephrotic syndrome, hypercalcemia, severe hepatic dysfunction, and patients with a history of myocardial infarction or coronary artery disease.
No specific food interactions reported. However, maintain a balanced diet low in saturated fats and sodium to mitigate adverse lipid and cardiovascular effects. Avoid excessive alcohol consumption due to hepatotoxicity risk.
Avoid grapefruit juice as it may increase ergonovine levels. No other significant food interactions.
Nandrolone is excreted into breast milk. The milk-to-plasma ratio is not established. Androgens may suppress lactation and cause virilization in the nursing infant. Use during breastfeeding is contraindicated.
Ergonovine is excreted into breast milk. The M/P ratio is not well established, but small amounts are detectable. It may cause adverse effects in the nursing infant, including vomiting, diarrhea, and transient hypertension. Because of the risk of ergotism in the infant, breastfeeding is generally not recommended during therapy. A decision should be made to discontinue breastfeeding or discontinue the drug, considering the importance of the drug to the mother.
No dosing adjustments are applicable as DURABOLIN is contraindicated in pregnancy. No pharmacokinetic data in pregnancy to guide dose modification.
No dosing adjustments are recommended or studied because use in pregnancy is contraindicated. If exposure occurs accidentally or for life-threatening indications (e.g., severe postpartum hemorrhage), the same doses used in non-pregnant adults (0.2 mg IM or IV) may be employed, but with extreme caution due to heightened sensitivity to uterotonic effects. No pharmacokinetic studies in pregnancy exist; however, increased plasma volume and altered hepatic metabolism may require careful titration, but no specific evidence supports dose changes.
This medication is for intramuscular injection only; do not inject intravenously.,Report signs of liver problems (jaundice, dark urine, abdominal pain) or heart issues (chest pain, shortness of breath) immediately.,May cause changes in libido, acne, hair growth, or voice deepening; these may be irreversible.,Regular blood tests are required to monitor liver function, cholesterol, and blood count.,Do not share needles; proper disposal of used syringes is mandatory.,Avoid use during pregnancy and breastfeeding.,May interact with blood thinners (e.g., warfarin) and oral antidiabetics; advise dose adjustments.
This medication is given to control bleeding after childbirth.,It may cause nausea, vomiting, or dizziness.,Report severe headache, chest pain, or vision changes immediately.,Avoid smoking or using nicotine products while on this drug.,Do not breastfeed within 12 hours after the last dose; discuss with your doctor.